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Background: Malaria invasion of red blood cells involves multiple parasite-specific targets that are easily accessible
to inhibitory compounds, making it an attractive target for antimalarial development. However, no current antimalarial
agents act against host cell invasion.
Results: Here, we demonstrate that the clinically used macrolide antibiotic azithromycin, which is known to kill human
malaria asexual blood-stage parasites by blocking protein synthesis in their apicoplast, is also a rapid inhibitor of red
blood cell invasion in human (Plasmodium falciparum) and rodent (P. berghei) malarias. Multiple lines of evidence
demonstrate that the action of azithromycin in inhibiting parasite invasion of red blood cells is independent of
its inhibition of protein synthesis in the parasite apicoplast, opening up a new strategy to develop a single drug
with multiple parasite targets. We identified derivatives of azithromycin and erythromycin that are better invasion
inhibitors than parent compounds, offering promise for development of this novel antimalarial strategy.
Conclusions: Safe and effective macrolide antibiotics with dual modalities could be developed to combat malaria
and reduce the parasite’s options for resistance.
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Malaria is a mosquito-borne parasitic disease, which
causes nearly 600,000 deaths every year, mainly in chil-
dren under 5 years of age in sub-Saharan Africa [1].
Most deaths are attributed to the most virulent human
malaria parasite, Plasmodium falciparum. Current dis-
ease control measures rely on reducing exposure to the
mosquito vector or treatment of clinical malaria cases
with antimalarial drugs that target the disease causing
blood-stage trophozoite; most of these act against the
parasite’s food vacuole or interfere with pyrimidine syn-
thesis of maturing trophozoites [2–6]. Of major concern* Correspondence: danny.wilson@adelaide.edu.au; beeson@burnet.edu.au
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creativecommons.org/publicdomain/zero/1.0/is the emerging development of drug resistance to the
highly effective artemisinin family of compounds in
Southeast Asia [7–9]. The prospect of widespread resist-
ance to the most effective antimalarials becoming
entrenched has led to the implementation of an emer-
gency response plan by the World Health Organization
(WHO) to prevent the spread of resistance and the inev-
itable increase in childhood mortality that would result
[10]. This developing emergency highlights the urgent
need for new antimalarials with novel mechanisms of ac-
tion for use in combination with artemisinins, or to re-
place these drugs in the future.
Invasion of blood-stage merozoites into host cells has
been proposed as a potential target for antimalarial
chemotherapy [11–14]. Invasion of the extracellular
merozoite into a new host erythrocyte (red blood cell) is
a complex process requiring the coordinated interaction
of unique parasite ligands, signaling pathways, and article distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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motor. The multiple accessible targets make this essen-
tial stage of the lifecycle an attractive drug target. In
addition, inhibition of merozoite invasion into the
erythrocyte would lead to instant disruption of the para-
site lifecycle and prevent sequestration, dormancy and
commitment to the mosquito-transmissible gametocyte
stage, which have been reported to occur after drug
treatment with current first-line antimalarials [15–17].
Application of antimalarial drugs that target invasion
has the potential to result in quicker resolution of clin-
ical disease if used in combination with antimalarials
that act at other developmental stages.
Few compounds have been directly tested for ability to
inhibit P. falciparum merozoite invasion, partly through
lack of tractable invasion inhibition assays. The ability to
assess the invasion inhibitory potential of compounds
and their biological activity in vitro has been greatly en-
hanced with the development of a robust and efficient
merozoite purification protocol and techniques to dir-
ectly measure invasion inhibition [13, 18–20], allowing
the accurate and rapid assessment of a compounds inva-
sion inhibitory potential. While some invasion inhibitory
compounds (e.g. protease inhibitors [18, 21, 22], heparin
[23] and calcium signaling modulators [23, 24]) have
been reported, to date no drug used clinically to treat
malaria has been shown to have inhibitory activity
against merozoite invasion [13]. In this study, we have
identified clinically relevant macrolide antibiotics and re-
lated compounds, exemplified by azithromycin, as rapid
inhibitors of P. falciparum and P. berghei merozoite in-
vasion in vitro. This represents the first time that a drug
or drug class that has clinical applications against mal-
aria has been demonstrated to inhibit parasite invasion
of the red blood cell.
Antibiotics such as azithromycin and clindamycin
(lincosamide antibiotic) have been proposed as potential
partner drugs for artemisinin combination therapies
owing to their extremely long half-life and good safety
profile in vivo [25–29]. Both azithromycin and clindamy-
cin inhibit apicoplast ribosomal protein synthesis of
asexual blood-stage parasites at nanomolar (clinical)
concentrations by binding to the apicoplast ribosomal
50S subunit and blocking protein exit from the ribosome
[30–32]. In vitro experiments at clinically relevant con-
centrations show that these antibiotics have a ‘delayed
death’ drug response. Treated parasites grow normally
during the first lifecycle under treatment. Only during
the second post-treatment cycle (after replication and re-
invasion) are drug effects observed. Parasite death at this
stage is thought to result from the inheritance of a
defective apicoplast that is unable to synthesize isopren-
oid precursors required for development [31–33]. This
‘delayed death’ response currently limits the usefulnessof azithromycin and clindamycin for the treatment of
clinical disease as stand-alone drugs, and successful com-
binations with other antimalarials remain elusive [34].
In this study, we aimed to identify existing, and novel,
compounds with invasion inhibitory activity that have
the potential for development as effective antimalarials.
We demonstrate that the antibiotic azithromycin can
specifically inhibit merozoite invasion. Related macrolide
antibiotics were also found to inhibit invasion, and the
IC50 of invasion inhibitory activity could be lowered
through modification. These results provide the basis for
a novel strategy of antimalarial drug development by
advancing compounds that have dual mechanisms of
action. Given the established safety and low cost of
macrolides in widespread clinical use, development of
macrolides as antimalarials with dual modalities against
merozoite invasion and protein translation in the apico-
plast is a promising strategy to counter the rapid emer-
gence of drug resistance.
Results
Azithromycin inhibits merozoite invasion
Application of the merozoite purification method of
Boyle et al. [18] identified the macrolide antibiotic
azithromycin as a candidate inhibitor of P. falciparum
asexual blood-stage merozoite invasion of the host
erythrocyte (see Fig. 1a for representation of assay setup,
Fig. 2 for structure of azithromycin and other drugs used
in this study). Initial screens indicated that the invasion
inhibitory IC50 differed between azithromycin prepared
in ethanol (10 μM) or DMSO (38 μM), suggesting that
choice of vehicle can impact azithromycin potency
in vitro. Comparative screens of azithromycin potency
over different treatment times demonstrated that the
IC50 of merozoite invasion assays (1 hour exposure to
drug) were surprisingly similar to the in cycle (40 hour
incubation, no invasion step, Fig. 1b) and 1 cycle (90 hour,
one invasion step, Fig. 1c) assays (IC50 –(drug pre-
pared in ethanol) invasion 10 μm; in cycle 6 μM; 1
cycle 7 μM, −(drug prepared in DMSO) invasion 38 μM
(DMSO); in cycle 12 μM; 1 cycle assay 7 μM, Fig. 3a,
Table 1). These results suggest that azithromycin can act
independently against both merozoite invasion and intra-
cellular parasite growth within one cycle of treatment
in vitro.
To confirm that azithromycin was inhibiting merozo-
ite invasion directly in our assays and was not acting
downstream of invasion during intracellular parasite
growth, the effect of exposure of merozoites or early
ring-stage parasites to the drug was examined; azithro-
mycin was washed out of the cultures within 1 hour and
parasitaemia assessed by flow cytometry 40 hours post-
assay setup for all treatments (prior to the next round
of parasite rupture and invasion of new host cells).
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Fig. 1 Drug treatment strategies used in this study. The lifecycle stage of drug treatment is represented in the first box for each panel and the
stage of parasitaemia measurements are highlighted by red boxes with yellow background. (a) Merozoite; successful invasion of drug-treated
purified merozoites was measured at ring-stage immediately after addition of erythrocytes and merozoite invasion (<1 hour rings) or after
washing out the drug (denoted by green dashed line) and growing parasites through to late trophozoite stage (40 hours post-invasion).
(b) In cycle; early ring-stage parasites (<4 hours post-invasion) were drug-treated and the resulting growth inhibition was assessed at late
trophozoite stage (40 hours post-invasion). (c) 1 cycle; early ring-stage parasites (<4 hours post-invasion) were drug-treated and the resulting
growth inhibition was assessed 90 hours later, after 1 cycle of reinvasion, at late trophozoite stage. These assays are a longer duration, but
nonetheless equivalent in terms of including 1 cycle of reinvasion and development, to 1 cycle assays reported in other studies [41–44]. (d) 2
cycle (delayed death); early ring-stage parasites (<4 hours post-invasion) were drug-treated and the drug-treated parasites were grown for 80
hours prior to washing out the drug in fresh media (denoted by green dashed line). Growth inhibition was assessed approximately 40 hours
later after a second cycle of reinvasion (120 hours post-invasion). (e) Live filming; mature schizont-stage parasites were incubated with azithromycin
and the success of merozoite invasion was recorded and quantified by live filming (green arrow, successful invasion; blue arrow, deformation of the
erythrocyte but no invasion; red arrow, attachment and release or attachment with failure to deform erythrocyte and no release) (see Additional file 1:
Video S1 and Additional file 2: Video S2). White box-drug treatment; yellow box-analysis of parasitaemia; green dashed line-drug washout
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early ring stages for less than 1 hour (T = 0) with azi-
thromycin (1 × IC80
mero DMSO 151 μM) and the invasion
inhibitory control compound, heparin, was significantly
more inhibitory to parasite growth than the same treat-
ment of early ring stages at the time-point of 20 minutes
post-invasion (T = 20 (exposed for 40 minutes); azithro-
mycin P <0.001; heparin P <0.01). Additionally, pretreat-
ment of erythrocytes, followed by washout of drug, had
little or no inhibitory effect on invasion (Fig. 3b; azithromy-
cin P <0.001; heparin P <0.001). This indicated that expos-
ure of merozoites, but not very early ring stages or
uninfected erythrocytes, was inhibitory to parasite growth.
In order to confirm that the inhibitory activity was
against purified merozoites and not the uninfectederythrocyte prior to merozoite invasion, erythrocytes
were pretreated with azithromycin at a 10 × IC80
mero
(380 μM (drug prepared in ethanol to limit nonspe-
cific effects of vehicle)) prior to washing and addition
of merozoites. There was minimal loss of invasion
into erythrocytes pretreated with a 10 × IC80
mero con-
centration of azithromycin for 1 hour relative to control
(Fig. 3c). In contrast, merozoites treated for 10 minutes
with the same concentration of azithromycin were unable
to establish erythrocyte infections (P <0.001), supporting
the conclusion that it is the merozoite and its interaction
with the erythrocyte, and not the erythrocyte itself, that
is the target of inhibition.
Next we confirmed that azithromycin was inhibiting
merozoite invasion directly, rather than acting on growth
AB
C D
Fig. 2 Structure of macrolide antibiotics. (a) Structure of the 15-membered macrolide, azithromycin, and its modified analogues (names used in
the text underlined, in brackets). (b) Structure of the 14-membered macrolide, erythromycin A, and its modified analogues. (c) Structure of
the 16-membered macrolide, spiramycin. (d) Structure of the non-macrolide antibiotic, clindamycin
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methods of microscopy and flow cytometric quantification
of ring-stage parasites at the time-point of 1 hour post-
invasion. There was an almost complete loss of ring-stage
parasites seen by both microscopy and flow cytometry for
azithromycin (1 × IC80
mero), confirming that azithromycin is
indeed inhibitory to merozoite invasion (Fig. 3d,e,f). The
merozoite invasion inhibitory activity of azithromycin was
unaffected by limiting drug exposure to <5 seconds prior
to erythrocyte addition, by the presence of serum in the
culture medium or the presence of haemazoin crystals(that can remain after purification of merozoites) in the in-
vasion assay. These results demonstrate that azithromycin
is a rapid inhibitor of merozoite invasion in vitro.
Azithromycin inhibits merozoite invasion prior to tight
junction formation
Live cell imaging of invading Plasmodium merozoites in-
dicates that erythrocyte invasion is a multi-step process
that typically takes less than 30 seconds to complete,
after contact occurs between the merozoite and the
erythrocyte, in primate species and slightly longer in
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Fig. 3 Azithromycin inhibits P. falciparum merozoite invasion. (a) The potency of azithromycin in ethanol or DMSO as vehicle was compared for
invasion inhibition (unbroken line, 10 minute merozoite treatment, parasitaemia measured 40 hours later) and 1 cycle growth inhibition assays
(broken line, treatment rings to trophozoites’ next cycle). The invasion inhibitory IC50 of azithromycin prepared in ethanol (blue, IC50 10 μM) was
similar to that for growth inhibition assays (IC50 7 μM; P = 0.0743, Log IC50 same between data sets, extra sum of squares F-test). The invasion
inhibitory activity of azithromycin in DMSO (red, IC50 38 μM) was 5-fold higher than 1 cycle growth assays (IC50 7 μM; P <0.0001, Log IC50 different
between data sets). (b) Inhibition profiles for pretreated erythrocytes (RBC Pre), merozoite treatment (T = 0; drug added at time zero) and rings
treated for <1 hour (T = 20; drug added 20 minutes post-invasion) were identical between azithromycin (in DMSO) and the invasion inhibitor
heparin (IC80 concentration). (c) Increasing the concentration of azithromycin (in ethanol) to 10 × IC80 (380 μM) did not result in substantial
inhibition of invasion into pretreated cells compared to treatment of merozoites. (d) Flow cytometry and microscopy assessments confirmed
that azithromycin (IC80 in ethanol) and heparin, but not the trophozoite-targeting antimalarial halofantrine (2 × IC80 ring-stage treatment
(46 nM) [13]), inhibit merozoite invasion and establishment of ring stages in erythrocytes. Representative (e) flow cytometry plots (GFP
high and EtBr low ring-stage parasites represented by square gate) and (f) microscopy thin smears (rings highlighted by green arrows)
show absence of ring-stage parasites for azithromycin and heparin compared to non-invasion inhibitory controls (labeling as per Fig. 3d).
Experiments represent the mean and SEM of three or more experiments. Significance was tested using an unpaired t-test (*P = 0.01–0.05, **P ≤0.01,
***P ≤0.001)
Wilson et al. BMC Biology  (2015) 13:52 Page 6 of 19rodent species [35–37]. After contacting its target
erythrocyte, the merozoite reorients its apical end onto
the erythrocyte surface in a process that deforms the
erythrocyte. This reorientation lasts about 10 seconds
and is followed by the formation of a ring-like region
of close and irreversible contact, called the tight (or
moving) junction, between the merozoite apex and theTable 1 Growth/invasion inhibitory activity of compounds described
Compound
number
Compound
abbreviation
Compound name Lactone ring
size
1 AZRa Azithromycin 15
2 AZR-desclada - 15
3 AZR-desglycana - 15
1 AZRb Azithromycin 15
4 12eb,c - 15
5 1jb,c - 15
6 11cb,d - 15
7 7/47b,e - 15
8 7/25b,e - 15
9 ERYa Erythromycin 14
10 ERY-desclada - 14
11 ERY-oximea - 14
12 ROXa Roxithromycin 14
13 DIRa Dirithromycin 14
14 Meg-ERYa,f 6-0-megosaminyl-erythromycin 14
15 SPIa Spiramycin 16
16 CLIa Clindamycin NA
D10-AZRr (delayed death, resistant) comparison
1 AZRa Azithromycin 15
1g AZRa Azithromycin 15
aVehicle was ethanol; bvehicle was dimethyl sulfoxide (DMSO); cfrom Bukvic et al. [4
All IC50s are for the D10-PfPHG line used throughout this study, with the exception
made as per Goodman et al. [41]. All assays were measured by flow cytometry, w
Desclad, descladinosyl; desglycan, descladinosyl and desosaminyl; NA, not applicaberythrocyte. The merozoite enters the host cell through
this junction using the power of its actin-myosin motor.
After invasion, the erythrocyte surface reseals and the
merozoite differentiates into a ring-stage parasite over
several minutes [35]. We used live cell imaging to iden-
tify invasion step(s) that are inhibited by azithromycin
(Fig. 1e). Late schizont-stage parasites were allowed toin this study
IIA IC50 (μM) 40 hour IC50 (μM) 90 hour IC50 (μM) 120 hour IC50 (μM)
10 6 7 0.04
50 39 31 ND
>1,600 >500 285 ND
38 12 7 0.1
15 1 0.6 0.16
7 0.9 0.7 0.16
28 ND 0.9 ND
52 ND 5 ND
73 ND 10 ND
420 230 52 ND
ND 288 185 ND
150 85 24 ND
83 70 27 ND
521 15 8 ND
13 ND ND ND
123 15 13 ND
743 ND ND ND
- - - 0.16g,h
25 ND ND 9h
4]; dfrom Peric et al. [42]; efrom Hutinec et al. [43]; ffrom Goodman et al. [41].
of gwhich were undertaken with the D10 azithromycin-resistant line (D10-AZRr)
ith the exception of hwhich were measured by hypoxanthine uptake assays.
le; ND, not done
Wilson et al. BMC Biology  (2015) 13:52 Page 7 of 19rupture in the presence of 75 and 134 μM azithromycin
(in ethanol), which represent 2 × IC80 and 3.5 × IC80 of
merozoite invasion inhibition concentrations, respect-
ively. These slightly higher drug concentrations were
used to clearly define the inhibitory phenotype. These
concentrations were not found to inhibit schizont rup-
ture. Five schizont ruptures were observed for each
treatment. In the untreated control, 22 merozoites were
observed to contact erythrocytes. After a contact period
ranging from a few seconds to 2 minutes, 18 % of the
merozoites released or detached. A further 32 % of the
merozoites progressed to the erythrocyte deformation
stage before releasing over a few minutes, and the
remaining 50 % advanced to complete invasion (Fig. 4).
Azithromycin treatment at 75 μM changed this profile
with fewer merozoites invading (32 %) and a greater pro-
portion failing to progress beyond the initial contact and
deformation stages (68 %, Fig. 4). At 134 μM there was a
significant and dramatic change in the invasion profile
compared to the untreated control and azithromycin
treatment at 75 μM with no merozoites invading and
most releasing after initial contact (81 %, Fig. 4). The ob-
servation that merozoites failed to make sustained contact
with erythrocytes in the presence of azithromycin indicates
that azithromycin acts early in invasion to prevent tight
junction formation [23, 35, 38]. The periods of time that
each of the invasion steps took to occur was also measured,
but in nearly all cases showed no significant difference be-
tween the treatments. Representative video files showing
the effects of azithromycin are shown in Additional file 1:
Video S1 and Additional file 2: Video S2.0 µM 75 µM
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Fig. 4 Azithromycin inhibits the early steps of invasion. Video microscopy o
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invade (contact–deform). From several rupturing schizonts, the number o
drug treatment and the percentages are shown along with the number
indicate significant differences at the following levels (**P ≤0.01, ***P ≤0Macrolides related to azithromycin also inhibit merozoite
invasion
After identifying that azithromycin was inhibitory to
merozoite invasion, we examined whether related drugs
with a history of clinical use as antibiotics also had this
property. Macrolides with a 14-membered macrolactone
ring (erythromycin A, roxithromycin, dirithromycin) and
16-membered ring (spiramycin) were tested using the
same methods as azithromycin (prepared in ethanol,
Fig. 2b,c). Determination of the inhibitory concentration
(Fig. 5a,b,c,d; Table 1) indicated that azithromycin (ethanol,
10 μM) had >8-fold lower IC50 for merozoite invasion
when compared to roxithromycin (83 μM) and spiramycin
(123 μM), while erythromycin (420 μM) was 42-fold less
potent than azithromycin. Of interest was the very poor in-
vasion inhibitory activity of dirithromycin (521 μM), which
was 52-fold less potent than azithromycin, even though the
IC50 values determined using 1 cycle growth assays were
very similar (dirithromycin, IC50
90hr 8 μM; azithromycin,
IC50
90hr 7 μM; Table 1). Invasion inhibition was confirmed
by measurement of ring-stage parasites 1 hour after inva-
sion at 1 × IC80
mero for erythromycin A, roxithromycin and
spiramycin. The lack of inhibitory activity when erythro-
cytes were pretreated with drug (and then washed) further
confirmed specific inhibition of merozoite invasion (Fig. 5e;
P <0.01).
Merozoite invasion inhibition is independent of macrolide
activity against apicoplast ribosomes
Since macrolide antibiotics are known to target the 50S
ribosomal subunit of the apicoplast to inhibit subsequent134 µM
Contact - release
Contact - deform
Contact - invade3
13
0
f merozoite invasion of erythrocytes was performed in the presence
l (0 μM). Five schizont ruptures were observed for each treatment. Of
eform erythrocytes and then successfully invade their host cells
ent (contact–detach) or progressed to deformation but did not
f merozoites exhibiting each of these steps was counted for each
of events in the column boxes. A Chi-squared test was performed to
.001)
Wilson et al. BMC Biology  (2015) 13:52 Page 8 of 19intra-erythrocytic development, we tested the invasion
inhibitory activity of clindamycin, which has a similar
mechanism of action and exhibits overlapping binding
of the 50S ribosomal subunit of the apicoplast to azi-
thromycin [39] (Table 1; Fig. 2c). Clindamycin had very
weak invasion inhibitory activity; there was evidence for
invasion inhibitory activity with a 74-fold higher IC50
observed for clindamycin (IC50
mero 743 μM) than seen for
azithromycin (10 μM). However, pre-treatment of eryth-
rocytes with 2,972 μM of clindamycin (IC80
mero) resulted
in a 65 % reduction in merozoite invasion relative toA
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(c) dirithromycin (521 μM) and (d) the 16-membered macrolide spiramycin
a higher IC50 than that achieved for 1 cycle assays (red). (e) The invasion in
IC80 concentration was confirmed by flow cytometry assessment of ring
All experiments represent the mean and SEM of three or more experim
t-test (**P ≤0.01, ***P ≤0.001)untreated controls and there was evidence of erythrocyte
lysis using these high levels of clindamycin (Fig. 6a). This
suggests that at such high concentrations clindamycin is
having a largely non-specific effect on merozoite inva-
sion through damaging erythrocytes.
We tested further whether apicoplast ribosomal pro-
tein translation was the target of the inhibitory activity
at the merozoite stage by comparison of the invasion
inhibitory activity of azithromycin, erythromycin and
clindamycin between the D10-PfPHG (azithromycin-
sensitive) parasite used throughout this study and anB
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stages with minimal inhibition evident for pretreated erythrocytes.
ents. Significance of differences was compared using an unpaired
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lected for reduced sensitivity to both azithromycin and
erythromycin in 2 cycle (delayed death) assays. Sequen-
cing of apicoplast ribosome genes revealed a G91D mu-
tation in the rpl4 gene product, corresponding to the
G112D mutation in Chlamydomonas reinhardtii, known
to confer resistance to erythromycin [40]. This mutation
is associated with a 57-fold loss of sensitivity to azithro-
mycin over 2 cycles of parasite growth (IC50
120hr D10-
AZRr, 9 μM; D10 parental, 0.16 μM; P <0.0001; Fig. 6b;
Table 1). Comparison of the IC50
mero (Fig. 6c,d,e) sug-
gested that there was very little difference in merozoite
invasion inhibitory activity between the resistant versus
sensitive lines for azithromycin (in ethanol, 2.5-fold dif-
ference; IC50 D10-AZR
r, 25 μM; D10-PfPHG, 10 μM;
P <0.0001), erythromycin (1.6-fold difference; IC50 D10-
AZRr, 732 μM; D10-PfPHG, 442 μM; P = 0.0247) or
clindamycin (1.3-fold difference; IC50 D10-AZR
r, 556
μM; D10-PfPHG, 736 μM; P = 0.26). Together, these
data suggest that the invasion inhibitory activity of azi-
thromycin is largely independent of apicoplast ribosomal
protein synthesis, consistent with the current view that
the apicoplast does not play a role in invasion.
Modification of macrolides enhances invasion inhibitory
activity
We tested a panel of macrolide analogues to determine
whether the IC50 of merozoite invasion inhibition could
be reduced. An erythromycin A L-megosamine sugar de-
rivative (Meg-erythromycin, 6-O-megosaminyl erythro-
mycin A) that has a lower IC50 in 1 cycle growth
inhibition assays [41] was tested and found to reduce the
IC50 of merozoite invasion inhibition (13 μM) 32-fold
compared to the parent compound (420 μM; Fig. 7a;
Table 1; Fig. 2b). Furthermore, addition of an oxime
group (N-OH) to erythromycin A (erythromycin oxime)
lowered the invasion inhibitory IC50 (150 μM) almost
3-fold compared to erythromycin A. The increased po-
tency of Meg-erythromycin and erythromycin oxime
compared to the parent drug indicates that various
modifications to macrolides can lead to more potent
invasion inhibitory activity.
Next we obtained a small panel of azithromycin ana-
logues (in DMSO) from GlaxoSmithKline (Tres Cantos,
Spain) [42–44] with reported IC50 values lower than azi-
thromycin in a 72 hour growth inhibition assay (roughly
equivalent to 1 cycle assays in this study; Fig. 1c). In our
studies, we found that azithromycin dissolved in DMSO
was less effective so the following comparisons use the
IC50 values for both azithromycin and the azithromycin
analogues with DMSO as the solubilization vehicle. Two
compounds (12e, 15 μM; 1j, 7 μM) had a substantially
lower IC50 for merozoite invasion inhibition than azi-
thromycin (38 μM (when prepared in DMSO); Fig. 7b;Table 1; Fig. 2a), indicating that azithromycin can also
be modified to lower its invasion inhibitory activity
in vitro.
When early ring-stage parasites were treated with the
compounds 1j and 12e for 40 hours (in cycle; 1j, 0.9 μM;
12e, 1 μM) and 90 hours (1 cycle; 1j, 0.7 μM; 12e,
0.6 μM) the IC50 of the modified analogues was be-
tween 10- and 14-fold lower than that of azithromy-
cin (DMSO; in cycle, 12 μM; 1 cycle, 7 μM; Fig. 7c;
Table 1). In contrast, parasites treated for 120 hours
(2 cycle; delayed death, Fig. 1d) showed a small increase
in the potency of azithromycin (DMSO, 0.1 μM) over 1j
(0.16 μM) and 12e (0.16 μM) for the ‘delayed death’ in-
hibition typical of apicoplast ribosome targeting (Table 1).
This would suggest that the apicoplast ribosome target-
ing is not affected by the modifications of 1j and 12e, and
is a further indication that invasion inhibition or parasite
growth inhibition over 1 cycle of parasite growth or less
is not a result of inhibition of apicoplast ribosome activ-
ity. Further, the ability of azithromycin and its analogues
to inhibit intracellular parasite growth during in cycle as-
says (from early rings to late trophozoites) at IC50 values
lower than the invasion inhibition assays suggests that
the compounds can inhibit parasite growth independent
of merozoite invasion.
In order to assess whether the invasion inhibitory
phenotype of a more potent analogue was similar to our
observations for azithromycin in ethanol (see Fig. 4b),
live filming of merozoite invasion in the presence of
analogue 12e was examined using live video microscopy.
As was observed in Fig. 4, for the no drug treatment
control 53 % of merozoites that contacted an erythrocyte
invaded, 29 % deformed but failed to invade the erythro-
cyte after contacting and 18 % released the erythrocyte
membrane without invading or deforming the erythrocyte
(Fig. 7d). In contrast, addition of 12e at 122 μM (2 × IC80)
reduced invasion to only 8 % of total contact events, re-
duced contacts leading to erythrocyte deformation to 27
% of contact events and increased the number of merozo-
ites releasing without invading or deforming the erythro-
cyte to 65 % of all contact events, resulting in failure to
invade for 92 % of all contact events. These results sup-
port the live filming observations for azithromycin in
ethanol (Fig. 4b) and again indicate that azithromycin acts
early in the invasion process and inhibits tight junction
formation. We compared the invasion phenotype of 12e
to that of azithromycin in DMSO at an equal concentra-
tion (approximately 1 × IC80 of azithromycin in DMSO).
As expected, at the same concentration the less potent
parent azithromycin was less inhibitory to invasion (25 %
contact events invaded) and as a result had fewer failed in-
vasion events (75 %). Together, these findings establish a
proof-of-concept that macrolides with more potent
invasion inhibitory activity can be developed through
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invasion inhibition and other inhibitory activities can be
developed in single compounds and are not mutually
exclusive.Identification of structural groups on azithromycin
important for invasion inhibitory activity
We sought to identify structural groups of azithromycin
that were most important for invasion inhibitory activity
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glycosylated groups. The two glycan groups of azithro-
mycin, in particular the desosamine group, have been
identified as critical to proper drug binding and inhib-
ition of bacterial ribosome translation [39]. Removal of
the cladinosyl group (descladinosyl) for both azithromy-
cin and erythromycin A led to an increase of the drugs
IC50 for both in cycle (azithromycin, 6 μM, AZR-
descladinosyl, 39 μM; erythromycin A, 230 μM, ERY-
descladinosyl, 288 μM) and 1 cycle (azithromycin, 7 μM;
AZR-descladinosyl, 31 μM; erythromycin A, 52 μM;
ERY-descladinosyl, 185 μM) drug assays (Table 1;
Fig. 2a,b). Similarly, removal of the cladinosyl group
from azithromycin (AZR-descladinosyl, 50 μM) led to
5-fold reduction in the invasion inhibitory activity of
the compound compared to azithromycin (azithromycin,
10 μM, Fig. 7e).
We were further able to remove both the cladinosyl and
desosamine groups from azithromycin (AZR-desglycan;
Fig. 7e; Table 1; Fig. 2a), which led to a dramatic loss of
invasion inhibitory activity and an increase in the IC50 be-
yond the limits of the assay (>1,600 μM). Comparison of
these compounds indicates that the cladinosyl group has a
role in lowering the IC50 of invasion inhibition for azithro-
mycin, but the presence of both the cladinosyl and
desosamine groups is critical for azithromycin’s invasion
inhibitory activity. While these data suggest that the deso-
samine group plays the critical role during invasion inhib-
ition, technical limitations prevented the selective removal
of the desosamine group.
Azithromycin inhibits P. berghei merozoite and Toxoplasma
gondii tachyzoite invasion, but not P. berghei sporozoite
invasion
To test whether azithromycin could inhibit invasion of
P. berghei, widely used as a murine model of malaria, we
purified merozoites [45] and allowed invasion to proceed
in the presence of azithromycin. Azithromycin inhibited
merozoite invasion of P. berghei at very similar concen-
trations to that seen for P. falciparum, with no evidence
of inhibition for parallel treatments of newly invaded
rings (Fig. 8a,b).
Since azithromycin was found to be an effective inhibi-
tor of merozoite invasion, we tested whether this drug
could also inhibit invasion of P. berghei sporozoites into
liver cells in vitro. The effects of azithromycin on P. ber-
ghei in vitro liver-stage infections following invasion
have been previously reported to be limited to retard-
ation of apicoplast development with no effect on overall
parasite growth (up to 65 hours) [46]; the effect of azi-
thromycin on sporozoite invasion has not directly been
examined. Initially, we assayed the ability of P. berghei
sporozoites to enter liver cells in vitro using an estab-
lished assay. GFP-expressing sporozoites were allowed tosettle on and invade HepG2 cells. After free sporozoites
were removed by washing, cells were fixed and then
antibody-labeled without cell permeabilization, thereby
preventing labeling of sporozoites that are inside host
cells. We then compared the number of labeled cells
(external) to the total number of cells (internal and ex-
ternal, as measured by GFP expression) to determine in-
vasion efficiency. There was a statistically significant, but
modest, effect indicating that azithromycin may inhibit
sporozoite invasion of hepatocytes at concentrations up
to 100 μM azithromycin (100 μM, 42 % reduction in cell
entry; (azithromycin prepared in ethanol); Fig. 8c). How-
ever, this assay is unable to robustly distinguish between
sporozoites traversing liver cells from those establishing
an infection. Therefore, to assess the impact of azithro-
mycin treatment on the establishment of successful in-
fection of liver cells, we repeated the treatment and then
allowed any successfully invaded sporozoites to develop
for 24 hours; this is a point at which parasites develop-
ing within the liver cell can be distinguished from any
remaining sporozoites that have not established infec-
tion. The number of parasites successfully establishing
an infection and forming a vacuole at 24 hours did not
differ between azithromycin-treated and control (ethanol-
treated) cultures. This suggests that while there was some
evidence of reduced sporozoite invasion of liver cells, this
did not result in measurably reduced hepatocyte infections
by P. berghei sporozoites (Fig. 8d).
We next explored whether azithromycin could in-
hibit invasion of the related apicomplexan parasite,
Toxoplasma gondii, which has orthologues of many
Plasmodium invasion proteins and a similar invasion
process [47]. There was a significant dose-dependent
inhibition of tachyzoite invasion at azithromycin con-
centrations (in ethanol) between 250 μM and 50 μM
(Fig. 8e). Azithromycin inhibited 47 % of tachyzoite
invasions at the highest concentration tested (250 μM)
compared to 90 % inhibition for the invasion inhibitory
control cytochalasin D (1 μM) [48] and the invasion
inhibitory IC80 of azithromycin against P. falciparum
merozoite (38 μM; in ethanol), clearly indicating that
azithromycin is a less potent inhibitor of T. gondii in-
vasion in vitro. Importantly, there was no evidence of
tachyzoite invasion inhibition in the presence of 500
μM erythromycin A, reflecting the results of the P. fal-
ciparum studies which showed that erythromycin A is
a poor inhibitor of merozoite invasion compared to
azithromycin. We next explored whether the azithro-
mycin analogue 12e, which was found to be a more po-
tent inhibitor of P. falciparum merozoite invasion than
azithromycin (DMSO as vehicle), had improved tachy-
zoite invasion inhibitory activity compared to azithro-
mycin. Analogue 12e (tested at 42 μM due to limited
compound availability) was found to be a consistently
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Wilson et al. BMC Biology  (2015) 13:52 Page 13 of 19more potent inhibitor of T. gondii tachyzoite invasion
(48 % inhibition compared to non-inhibitory control)
than much higher concentrations of azithromycin (250
μM, 24 % inhibition, Fig. 8e), suggesting that analogues
of azithromycin could be developed to have much
greater potency against T. gondii host cell invasion
than the parent compound. These data suggest thatazithromycin and analogues are effective inhibitors of
Plasmodium spp. merozoite and T. gondii tachyzoite
invasion, raising the possibility that azithromycin may
target proteins or events conserved between organ-
isms. However, there are clearly differences in drug po-
tency between parasites hence drugs will have to be
optimized to target invasion for each organism.
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Successful control and treatment strategies for malaria
currently rely on the availability of effective antimalarial
drugs. The emergence of resistance to the critically im-
portant artemisinin family of drugs [7–9] highlights the
need for new drugs to partner and replace current ther-
apies, and new drug development strategies. Drugs that
target merozoite invasion have been proposed as a novel
strategy for antimalarial development [11–14]. We have
applied robust methods for the purification of viable
P. falciparum merozoites and invasion assays [13, 18] to
screen for inhibitors of merozoite invasion. The anti-
biotic azithromycin and related compounds were identi-
fied as rapid inhibitors of P. falciparum merozoite
invasion into erythrocytes. This is the first time that an
antimalarial in clinical use has been linked to inhibition
of merozoite invasion in vitro, and the first clear identifi-
cation of antimalarial compounds with dual mechanisms
of action against merozoite invasion and intra-
erythrocytic parasite development. Live video micros-
copy revealed that azithromycin acts to prevent the
essential step of tight junction formation during invasion.
Furthermore, the inhibitory activity of azithromycin was
largely ablated by selective removal of glycan groups, and
we identified modified macrolides with increased potency
against merozoite invasion.
Azithromycin is a macrolide antibiotic with a 15-
membered macrolactone ring that is well tolerated and
safe for clinical use by children and pregnant women
[28]. Azithromycin and related macrolides are known to
inhibit ribosomal protein synthesis in the asexual-stage
parasite apicoplast by binding to the 50S subunit of the
apicoplast (70S) ribosomal complex [49, 50]. Typically,
clinical concentrations of azithromycin based on current
dosing regimens result in ‘delayed death’ of the parasite
in in vitro assays. The progeny of azithromycin-treated
parasites fail to form functional apicoplasts in the
daughter merozoites, thereby causing the death of the
second generation of parasites after treatment [31, 32].
Azithromycin has been considered a candidate for inclu-
sion in artemisinin combination therapies (ACT) and for
the prevention of malaria in pregnancy [51] due to its
safety and its long half-life (over 50 hours) [25, 27, 29].
In addition to its ‘delayed death’ effect on parasite
growth, azithromycin has been reported to kill parasites
within the first cycle of in vitro parasite growth at a drug
concentration just above reported peak plasma concentra-
tions [29, 32]. It has been speculated that inhibition of
parasite growth during the first cycle of treatment is a re-
sult of azithromycin having a secondary target in addition
to the apicoplast ribosome [32, 41]. Given growth inhib-
ition via apicoplast-targeting ‘delayed death’ is approxi-
mately 150-fold more potent than that achieved for 1
cycle growth inhibition in vitro, azithromycin is thoughtto act predominantly through targeting the apicoplast
when used clinically. Because of azithromycin’s safety pro-
file, several studies have investigated modifications to the
drug with a view to lowering the IC50 of short-term treat-
ment (1 cycle of growth) to the low nanomolar range [42–
44]. Yet despite this interest in azithromycin, the target of
drug inhibition during the first cycle of growth is un-
known, and the potential of this novel mechanism of ac-
tion as a clinical treatment remains unclear.
Several lines of evidence indicate that azithromycin
has a secondary mechanism and target(s) of action to in-
hibit invasion, in addition to binding to the 50S apico-
plast ribosomal subunit as described for the ‘delayed
death’ phenotype [31, 32]. Clindamycin, a smaller and
structurally unrelated antibiotic that has overlapping
binding sites to azithromycin on the apicoplast ribosome
[39], as well as an identical mode of action, had very lit-
tle invasion inhibitory activity. Selection of a D10 line
for resistance (57-fold reduced sensitivity) to azithromy-
cin in the 2 cycle ‘delayed death’ assays did not result in
a similar increase in resistance to azithromycin invasion
inhibition assays when compared to a parental D10
(‘delayed death’ sensitive) line. Comparison of azithro-
mycin and its modified analogues (1j, 12e) showed that
modifications increasing the potency of these ana-
logues over azithromycin in invasion inhibition, in
cycle (40 hour) and 1 cycle (90 hour) assays did not
appreciably increase the potency of the compounds
over 2 cycle ‘delayed death’ assays, suggesting the
mechanism of enhanced inhibitory activity was inde-
pendent of anti-ribosomal activity.
The near instantaneous inhibition of merozoite inva-
sion caused by azithromycin also suggests that this drug
can rapidly kill parasites through a secondary mechan-
ism of action. Typical ‘delayed death’ inhibition by
macrolide antibiotics results in the loss of apicoplast
functionality [31, 32], with this then leading to the loss
of isoprenoid precursor biosynthesis, the only essential
function of the apicoplast during blood-stage develop-
ment [33]. The long timeframes required for apicoplast
translation inhibition and the resulting ‘delayed death’
caused by macrolide antibiotics is in striking contrast to
the very rapid inhibition of merozoite invasion at higher
drug concentrations. Furthermore, removal of the apico-
plast in the experiments by Yeh et al. [33] was not re-
ported to result in an invasion defect. Combined, the
available evidence suggests it is very unlikely that the
apicoplast plays some as yet undefined role in merozoite
invasion and implicates a secondary mechanism of
action of azithromycin against invading merozoites.
Whether the mechanism of invasion inhibition and
intracellular asexual-stage parasite growth inhibition
(within 1 cycle in the absence of invasion inhibition) is
the same remains to be elucidated. However, the similar
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the intriguing possibility that this secondary mechanism
of action could be targeted throughout the disease caus-
ing blood-stage of P. falciparum malaria.
The ability of azithromycin to rapidly inhibit merozo-
ite invasion, in addition to the apicoplast-targeting
‘delayed death’ mechanism of action, is an exciting pro-
spect for the development of macrolide-based drugs in
combination therapies. This dual modality could see azi-
thromycin assist in rapid clearance of parasites as well as
offering longer-term treatment of the remaining low-
level blood and liver-stage parasites through its activity
against the apicoplast. Such a drug treatment strategy
has the potential to increase drug efficacy, while redu-
cing the chances for the development of resistance.
Although the in vitro merozoite invasion inhibitory
activity of azithromycin required drug concentrations at
the upper end of what is achieved clinically [29, 32], we
demonstrate that modification of the macrolides can
lead to a substantial improvement in invasion inhibitory
activity; this suggests that invasion inhibitory macrolides
could be developed as therapeutics. Addition of an
L-megosamine sugar to erythromycin A through an
in vivo fermentation process [41] produced a compound
with 32-fold greater invasion inhibitory activity than par-
ent erythromycin A. Furthermore, a selection of azithro-
mycin analogues [42–44] lowered the invasion inhibitory
IC50 by up to 5-fold. The azithromycin derivatives were
tested only when solubilized in DMSO due to limitations
in the amount of available material. Importantly, the use
of DMSO as vehicle for solubilization reduced the po-
tency of the parent compound azithromycin 4-fold rela-
tive to ethanol as vehicle. If this observation were to hold
true for the derivatives, the invasion inhibitory IC50 of
the compound 1j (5) [44] would be in the range of
1–2 μM.
The invasion inhibitory IC50 of azithromycin (10 μM)
and analogues (1j, 7 μM; 12e, 15 μM) is comparable to
that achieved for inhibitors that specifically target the
function of essential merozoite proteins. Two recent
proof-of-concept studies identified small molecule in-
vasion inhibitory compounds targeting interactions be-
tween essential invasion ligands RON4-AMA1 (inhibitory
range 30–6 μM) and MSP1-19 (replication inhibition
21.7 μM) [12, 14], and reported invasion inhibitory IC50
values in a very similar range to azithromycin and ana-
logues. Another highly selective invasion inhibitor, the
3D7-AMA1-specific peptide inhibitor R1 [52], has an in-
vasion inhibitory IC50 of 2.5 μM in assays using purified
merozoites [18]. Azithromycin, with minimal modifica-
tion, can rapidly inhibit merozoite invasion at concentra-
tions comparable to some of the best and most selective
invasion inhibitors available for drug development and re-
search. The encouraging improvements evident in theinvasion inhibitory activity of azithromycin from only a
small panel of derivatives, combined with the proven
safety and efficacy of macrolides, support the potential for
developing such compounds as therapeutics.
Removal of azithromycin’s glycan groups provided
insight into the structural requirements for invasion
inhibitory activity. Removal of the cladinosyl sugar
resulted in a 5-fold reduction in invasion inhibitory ac-
tivity. Strikingly, removal of both sugars resulted in
complete loss of invasion inhibitory activity, strongly
suggesting that the desosamine sugar, rather than the
cladinosyl, is critical for invasion inhibitory activity.
Interestingly, the desosamine sugar is also considered
the critical glycosylated group in binding of macrolides
to microbial ribosomes [39] with clinically used macro-
lide antibiotics such as telithromycin having dispensed
with the cladinosyl group altogether. Screening of a
larger number of macrolides and modified analogues will
help identify others with greater potency, and allow
assessment of which modifications and groups are most
important for activity.
The fact that azithromycin inhibits host invasion by
Plasmodium merozoites (from human and rodent
malaria) and T. gondii tachyzoites parasites suggests that
the target of inhibition is shared amongst some apicom-
plexan invasive stages. The fact that the potency of azi-
thromycin against P. falciparum (human) and P. berghei
(rodent) malarias was very similar raises the possibility
that targeting this pathway could be an effective
strategy to treat other malaria species. The results of
the T. gondii invasion assays suggest that host cell
invasion of this more distantly related apicomplexan
parasite can also be targeted by azithromycin, albeit
at higher concentrations. Importantly, the analogue
12e had equal or better invasion inhibitory potency
than azithromycin (in ethanol or DMSO, respectively)
when tested at a 6-fold lower concentration. This
strongly suggests that analogues of azithromycin could
be developed with superior inhibitory activity against
tachyzoite invasion and confirms that the invasion inhibi-
tory activity of azithromycin and analogues is shared
across distantly related apicomplexan parasites.
Macrolide antibiotics have been linked to mechanisms
of action other than binding to microbial ribosomes,
including interference with intracellular signalling mech-
anisms such as Ca2+ and MAPK through an as yet un-
defined mechanism (reviewed in [53]). Intracellular Ca2+
signalling is thought to play an important role in
invasion (reviewed in [54]) so interference with this
mechanism by macrolide antibiotics could contribute to
inhibition of invasion. Macrolide antibiotics have also
been shown to bind to negatively charged phospholipid
bilayers and interfere with normal membrane function
[55, 56]. Intriguingly, the relative activity of the
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of cationic groups present on the macrolide.
Conclusions
The results of this study have identified for the first time
that macrolide antibiotics, a diverse group of well-
tolerated antibiotic drugs with antimalarial properties,
inhibit Plasmodium spp. merozoite invasion into eryth-
rocytes in vitro. Invasion inhibition assays and live film-
ing experiments show that azithromycin acts rapidly to
stop merozoite entry very early during the invasion
process. The mechanism of invasion inhibition appears
to be independent of apicoplast ribosomal translation in-
hibition, which is the currently described mechanism of
action of these drugs. Modification of both azithromycin
and erythromycin A resulted in promising reductions in
the invasion inhibitory IC50 to levels nearing those
achieved clinically for the parent compounds, providing
a proof-of-concept for the potential development of po-
tent invasion inhibitors. Elucidation of the mechanism of
action and subsequent improvements in compound po-
tency could pave the way for development of macrolide
antibiotics with dual modality as novel and potent
antimalarials to complement frontline treatments for
malaria. Furthermore, the use of drugs that inhibit mer-
ozoite invasion in combination with drugs that inhibit
intra-erythrocytic parasite development may be an ef-
fective strategy to facilitate rapid parasite clearance to
help improve clinical outcomes, reduce transmission,
and minimize the development of resistance.
Methods
Culture of P. falciparum
D10 parental and GFP fluorescent D10-PfPHG [57] para-
sites were cultured in human O+ erythrocytes (Australian
Red Cross, Victoria, Australia) according to established
protocols [57, 58]. Synchronization using heparin for
growth inhibition and merozoite invasion inhibition assays
has been described previously [13, 18, 23, 57]. Unless
otherwise stated, the D10-PfPHG isolate was used in assays
because the GFP label facilitates accurate quantification of
parasite stages by flow cytometry [13, 18].
Drug inhibition assays
A diagram outlining the different drug inhibition assays
used in this study to measure P. falciparum growth and
invasion inhibition is available in Fig. 1a,b,c,d,e. The
protocol for measuring drug inhibition of ring- and
trophozoite-treated parasites in cycle (approximately 40
hours post-invasion), 1 cycle (90 hours post-invasion, in-
cludes 1 cycle of replication) and 2 cycle (120 hour post
invasion, includes 2 cycles of replication) growth assays
has been described in detail previously [13, 57, 59]. Para-
sitaemia was measured at trophozoite stage by flowcytometry (BD FACSCalibur, BD Biosciences, Franklin
Lakes, NJ, USA) after staining with 10 μg/ml ethidium
bromide (EtBr) for 1 hour prior to washing in PBS. Typ-
ically, 20,000 to 40,000 erythrocytes were counted for
each well. Samples were analyzed using FlowJo software
(Tree Star Inc, Ashland, OR, USA).
Invasion inhibition assays
The protocols for filtration of viable P. falciparum and
P. berghei merozoites from E64-treated schizonts and
merozoite invasion inhibition assays have been previ-
ously described [13, 18, 45]. Parasitaemia was assessed
by flow cytometry of EtBr-treated rings (1 hour post-
invasion, 5 μg/ml EtBr, staining 10 minutes, no wash)
and trophozoite stages (as per 1 cycle assay). Early ring-
stage parasites were gated using a Fl-1 high (GFP) and
Fl-2 low (EtBr) gate. Trophozoites were gated using a
Fl-1 high (GFP) and Fl-2 high (EtBr) gate. Parasitized
erythrocytes for microscopy were fixed in methanol
and stained for 10 minutes in 10 % Giemsa (Merck,
Kenilworth, NJ, USA). For microscopy of fixed slides, the
number of early ring-stage parasites in a minimum of
1,000 RBCs was assessed by an experienced microscopist
in duplicate wells from three independent experiments.
Liver-stage assays used P. berghei ANKA sporozoites
dissected from infected Anopheles stephensi mosquitoes.
Two-color invasion assays followed the protocol of
Sinnis et al. [60] with the following modification. P. ber-
ghei constitutively expressing GFP [61] were added to
cultured HepG2 cells in the presence of inhibitory com-
pounds, centrifuged for 3 minutes at 150 g and then in-
cubated for 1 hour to allow invasion. The liver cell and
parasites were then fixed but not permeabilized. When
probed with polyclonal antibody against P. berghei mero-
zoite surface proteins [62] (500:1) followed by anti-
mouse Alexa Fluor 546 (1,000:1; Invitrogen, Carlsbad,
CA, USA) only uninvaded sporozoites are labelled.
Without permeabilization, the antibodies cannot pass
through the HepG2 cell plasma membrane, so sporozo-
ites within the liver cells are not labelled. Invasion rate is
calculated by comparing the number of labelled sporo-
zoites to the total number based on GFP expression.
Successful infection of hepatocytes was measured
through an extension of the invasion assay by adding the
parasites as above, incubating at 37 °C for 2 hours,
exchanging media and then incubating the liver-stage
parasites for a further 24 hours to allow development of
any intracellular parasites. The presence of developing
liver-stage parasites that had successfully invaded and
established infection was then quantified according to
previously published methods [63].
Toxoplasma gondii invasion assays were performed
using the Rh parasite strain according to existing proto-
cols [64] with the following modification. Inhibitory
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buffers prior to commencement of host cell invasion.
Parasites were allowed to invade for 15 minutes, fixed and
sequentially labeled with αSAG1 (2,000:1) and αGAP45
antibodies (500:1), followed by secondary labeling with
Alexa Fluor 488/543 (Invitrogen). Parasites were imaged
with a Leica SP2 confocal microscope (Leica, WETZLAR,
Germany) and a minimum of 1,000 parasites were counted
per well with three replicates for each concentration.
The IC50 and IC80 concentrations were determined
using GraphPad Prism (GraphPad Software, La Jolla,
CA, USA) as previously described [13]. The inhibitory
concentration (IC) for 1 cycle (90 hour), 2 cycle (‘delayed
death’, 120 hour) and merozoite (<1 hour post-invasion)
will be discriminated by the addition of 90hr, 120hr
and mero where appropriate.
Live cell microscopy
Live cell microscopy experiments were undertaken ac-
cording to the method of Weiss et al. [38]. Briefly, highly
synchronous late-stage schizonts were diluted 1:25 in
media ± drug treatment and allowed to settle to produce
a monolayer onto a 35 mm FluoroDish (World Precision
Instruments, Sarasota, FL, USA). At 37 °C on a Zeiss
Axio Observer.Z1 fluorescence microscope (Zeiss,
Oberkochen, Germany) equipped with humidified gas
chamber (90 % N2, 5 % O2 and 5 % CO2), selected
schizonts were observed until they ruptured and released
their merozoites. Time-lapse videos of the invading mer-
ozoites were recorded with a high-resolution AxioCam
MRm camera (Zeiss). ImageJ was used to perform image
analysis and GraphPad Prism used to perform statistical
analyses using a Chi-squared test.
Chemistry
A summary of the chemical structures of the com-
pounds used in this study is available in Fig. 2. Azithro-
mycin 1, erythromycin 9, erythromycin oxime 11 and
dirithromycin 13 were obtained commercially from Ak-
Scientific (Union City, CA, USA). Roxithromycin 12,
clindamycin 16 and spiramycin 15 were from Sigma
Aldrich (St Louis, MO, USA). 6-O-Megosaminyl erythro-
mycin A 14 was a gift from C Goodman, E Rodriguez
and H Gramajo [41]. Compounds 4–8 were provided by
GlaxoSmithKline (Tres Cantos, Spain). Synthesis of these
compounds are as previously described: 4 (12e) and 5 (1j)
[44]; 6 (11c) [42]; and 7 (7/47) and 8 (7/25) [43]. AZR-
desclad 2 was prepared according to Istuk et al. [65].
ERY-desclad 10 was prepared following methods of
LeMahieu et al. [66]. AZR-desglycan 3 was prepared
following similar procedures previously outlined in the
literature [67, 68]. In general, compounds were solubilized
with ethanol as vehicle, with the exception of the initial
characterization of azithromycin (1), where both ethanoland DMSO were compared, and compounds 4–8 (DMSO),
owing to the limited amount of material available.
Availability of supporting data
A tabular summary of data used to generate graphs and
perform statistical tests presented in this manuscript
(Figs. 3b,c; 4; 5e; 6a; 7d; and 8b,e,f ) is available in
Additional file 3.
Additional files
Additional file 1: Video S1. Video of newly egressed merozoites
revealed that of those that contact erythrocytes about half progress to
invasion (green arrows), whilst the remainder either detach after contact
(red arrow) or progress to deformation but fail to invade (blue arrow).
Additional file 2: Video S2. Video of newly egressed merozoites
from schizonts in the presence of azithromycin 134 μM revealed that
azithromycin inhibits early events in invasion; merozoites could attach
to erythrocytes but not invade (red arrows) and did not show evidence of
tight junction formation.
Additional file 3: Supporting data.
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